CAI Insider Filing: President Disclosed 63,509-Share Transaction at $29.75

Rhea-AI Filing Summary

David Baxley Spetzler, President of Caris Life Sciences (CAI), filed a Form 4 reporting a transaction dated 08/11/2025 in the issuer's common stock. The filing records 63,509 shares and a per-share price of $29.75, and shows 460,377 shares beneficially owned following the reported transaction, held directly. The form was signed by an attorney-in-fact on 08/13/2025.

Positive

• Full disclosure of key fields: transaction date, share amount, per-share price, and post-transaction beneficial ownership are provided
• Reporting person identified by role (President) and filing bears a dated signature by an attorney-in-fact

Negative

• Reported disposal of 63,509 shares (the filing shows the share amount and associated indicator)
• Transaction code 'F' is present but the filing contains no additional explanation or context for that code

Insights

Securities Analyst

Routine insider transaction disclosed: 63,509 shares at $29.75; post-transaction direct holdings 460,377 shares.

The Form 4 shows the issuer's President, David Baxley Spetzler, reported a transaction in common stock dated 08/11/2025. The filing lists 63,509 shares and a price of $29.75, with 460,377 shares reported as beneficially owned after the transaction and held directly. The disclosure is concise and includes a dated signature by an attorney-in-fact on 08/13/2025. The filing does not provide additional narrative context or explanation for the transaction code shown.

Corporate Governance Expert

Disclosure appears complete for required Form 4 fields; no explanatory context provided for the transaction code.

The report identifies the reporting person as the company's President and provides the transaction date, share amount, per-share price, and post-transaction beneficial ownership, all standard elements for Section 16 reporting. The form is executed by an attorney-in-fact. The filing does not include descriptive information about the purpose or circumstances of the transaction beyond the tabulated fields and the transaction code, which remains unexplained in the document.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Spetzler David Baxley

(Last) (First) (Middle)

C/O CARIS LIFE SCIENCES, INC.

750 W. JOHN CARPENTER FREEWAY, SUITE 800

(Street)

IRVING TX 75039

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Caris Life Sciences, Inc. [ CAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/11/2025		F		63,509	D	$29.75	460,377	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ J. Russel Denton, Attorney-in-Fact for David Baxley Spetzler	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for Caris Life Sciences (CAI)?

David Baxley Spetzler, identified as President, filed the Form 4 (signed by an attorney-in-fact on 08/13/2025).

What transaction is reported on the CAI Form 4?

A transaction dated 08/11/2025 in CAI common stock reporting 63,509 shares and a per-share price of $29.75.

How many CAI shares does the reporting person own after the transaction?

The filing reports 460,377 shares beneficially owned following the reported transaction, held directly.

Does the Form 4 explain the transaction code used?

The filing shows transaction code F but does not provide an explanatory note or narrative for the code.

When was the Form 4 signed?

The signature block shows 08/13/2025 with J. Russel Denton signing as attorney-in-fact for the reporting person.